Oridonin-loaded lipid-coated calcium phosphate nanoparticles: preparation, characterization, and application in A549 lung cancer. (28th May 2022)

• Record Type: Journal Article
• Authors: Shen, Yuzhou; Ma, Haitao
• Is Part Of: Pharmaceutical development and technology. Volume 27:Number 5(2022)
• Page Start: 598
• Page End: 605
• Publication Date: 2022-05-28
• Subjects: Oridonin -- lipid-coated calcium phosphate -- nanoparticles; Drug delivery systems -- Periodicals; Pharmaceutical technology -- Periodicals; Drugs -- Administration -- Research -- Periodicals; Drug Delivery Systems -- Periodicals; Pharmaceutical Preparations -- Periodicals; Technology, Pharmaceutical -- Periodicals; 615
• DOI: 10.1080/10837450.2022.2090958
• Languages: English
• ISSNs: 1083-7450

Abstract

Abstract: In this study, the feasibility of using the novel anisamide-lipid calcium phosphate nanoparticles (AS-LCPs) as a nanocarrier for the delivery of biologically active oridonin (ORD) was evaluated on lung cancer models. In addition to the characterization, release behaviors, and stability of AS-ORD LCPs, we also studied their pharmacokinetics and targeting ability by in vivo imaging. Finally, we investigated the effect of ORD on the anti-tumor efficiency of the AS-LCPs based on weight, tumor inhibition, and the survival time of mice. The average particle size of the AS-ORD LCPs was 129.5 ± 23.7 nm, the polydispersity index (PDI) was 0.16 ± 0.03, and the zeta potential was 23.6 ± 3.4 mV. The AS-ORD LCPs were proved to be stable under both long-term and accelerated storage conditions. The AS-ORD LCPs showed sustained release in vivo and faster release in acidic environment, which was favorable to drug release in tumor environment. In vivo studies showed that depending on surface modification, AS-ORD LCPs which suggested that cell internalization was change and more drugs entered the cells successfully. Therefore, AS-ORD LCPs could be a promising formulation for the treatment of lung cancer. Graphical Abstract: UF0001